Xencor

Xencor, Inc. is biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Xencor reports strong earnings, focuses on innovative pipeline strategies

Xencor's strong financial performance and promising pipeline programs position it well for growth
Unique mechanisms and designs offer competitive advantages in oncology and autoimmune disease treatments
Challenges like revenue expectations and validation requirements are being addressed strategically
Opportunities for collaborations and program optimizations pave the way for future success

Xencor advances internal portfolio with strategic focus on impactful targets

Xencor's Q1 2023 Earnings Call highlighted progress in their internal development portfolio, welcoming a new Chief Development Officer and emphasizing innovative therapeutic formats.
While facing challenges in data updates and program differentiation, the company's strategic focus on impactful targets and early clinical development positions them for future success.
Opportunities lie in expanding therapeutic programs, leveraging royalties, and exploring new avenues for growth, signaling a promising trajectory for Xencor in the biopharmaceutical landscape.

Xencor reports robust Q2 earnings and pipeline advancements

Xencor's Q2 2023 earnings call showcased strong performance in royalties and collaborations
The company's diverse pipeline and focus on safety and selectivity present opportunities
Challenges include addressing safety concerns and finalizing regimen for advancement
Overall, Xencor remains optimistic about future updates and pipeline progress

Xencor reports robust Q3 earnings, advances novel oncology therapeutics

Xencor's Q3 earnings call highlighted a strong financial performance, strategic pipeline adjustments, and progress in developing novel antibody-based therapeutics for oncology. The company is focused on maintaining asset potential through royalty deals and advancing internal pipeline candidates targeting solid tumors.

Xencor reports robust clinical data for vudalimab in prostate cancer

Xencor's Q4 earnings call showcased strong clinical data for vudalimab in prostate cancer, highlighting its efficacy and safety profile. The company's strategic focus on T-cell engagers and XmAb bispecific technology positions it well for future growth and innovation in solid tumor targeting.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will participate in a virtual fireside chat at the Barclays Global Healthcare Conference on Wednesday, March 10, 2021 at 2:25 p.m. ET / 11:25 p.m. PT. A live webcast will be available under "Events &

Xencor to Present at the Barclays Global Healthcare Conference

Xencor Inc (NASDAQ: XNCR) and UCLA Technology Development Group have agreed to develop novel therapeutic antibodies utilizing Xencor's modular suite of XmAb technology platforms.  Xencor's XmAb platforms are precisely engineered antibody Fc domains, which enable the creation of stable new protein structures.

Xencor, UCLA Ink Collaboration Pact For XmAb Therapeutic Candidates

MONROVIA, Calif. & LOS ANGELES--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, and UCLA Technology Development Group (UCLA TDG) today announced an agreement to develop novel therapeutic antibodies, pairing novel targets proposed by scientists at UCLA and utilizing Xencor's modular suite of XmAb® technology platforms. Xencor and UCLA have establi

Xencor and UCLA Enter Collaboration to Discover and Develop Novel XmAb® Therapeutics

Xencor Inc (XNCR) CEO Bassil Dahiyat on Q4 2020 Results - Earnings Call Transcript

Shares of Xencor (NASDAQ:XNCR) increased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 48.94% year over year to ($0.24), which beat the estimate of ($0.38).

Recap: Xencor Q4 Earnings

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a review of recent business and clinical highlights. "Throughout 2020, we advanced multiple clinical programs, introduced several new XmAb® bispecific technologies, and saw th

Xencor Reports Fourth Quarter and Full Year 2020 Financial Results

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will release fourth quarter and full year 2020 financial results after the market closes on Tuesday, February 23, 2021. Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and

Xencor to Host Fourth Quarter and Full Year 2020 Financial Results Webcast and Conference Call on February 23, 2021

Xencor (XNCR) signs a strategic research collaboration deal with MD Anderson Cancer Center to develop and commercialize T Cell-engaging bispecific antibodies for treating cancer.

Xencor (XNCR) Inks Deal for Novel Antibody Therapies in Cancer

MONROVIA, Calif. & HOUSTON--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and The University of Texas MD Anderson Cancer Center today announced a strategic research collaboration and commercialization agreement to develop novel CD3 bispecific antibody therapeutics for the potential treatment of patients with cancer. This collaboration joins Xencor's innovati

Xencor and MD Anderson Enter Strategic Collaboration to Develop Novel T Cell-Engaging Bispecific Antibodies for Potential Treatment of Patients with Cancer

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced it has entered into a research collaboration and license agreement with Janssen Biotech, Inc. (Janssen). The research and license agreement is focused on the discovery of XmAb® bispecific antibodies against CD28, an immune co-stimulatory receptor on T cells, and an undisclosed pr

Xencor Enters Collaboration with Janssen with Aim to Discover Novel CD28 Bispecific Antibodies for the Treatment of Prostate Cancer

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced updated data from its ongoing Phase 1 dose-escalation study of vibecotamab (XmAb®14045), a CD123 x CD3 bispecific antibody, in patients with relapsed or refractory acute myeloid leukemia (AML). The data were presented in an oral session at the 62nd American Society of Hematology (

Xencor Presents Updated Data from the Phase 1 Study of Vibecotamab in Acute Myeloid Leukemia at the 2020 ASH Annual Meeting

Incyte

Morphosys AG - ADR

MONROVIA, Calif. & PLANEGG/MUNICH, Germany & WILMINGTON, Del.--(BUSINESS WIRE)--Xencor (NASDAQ: XNCR), MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and Incyte (NASDAQ: INCY) today announced a clinical collaboration to investigate the combination of tafasitamab, plamotamab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), first-line DLBCL, and relapsed or refractory follicular lymphoma (FL). ‟Xencor is pleased to pa

Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced the presentation of new data from multiple preclinical XmAb® bispecific antibody programs and its preclinical IL-12-Fc cytokine program at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). "Our XmAb bispecific Fc domains were specifically created to enabl

Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the SITC Annual Meeting

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported data from its ongoing Phase 1 study evaluating XmAb®20717, a PD-1 x CTLA-4 bispecific antibody and Xencor's first tumor microenvironment activator, in patients with advanced solid tumors (DUET-2). The preliminary results from the study's expansion cohorts will be presented in a po

Xencor Presents Updated Data From the DUET-2 Phase 1 Study of XmAb20717, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting

Xencor Inc (XNCR) CEO Bassil Dahiyat on Q3 2020 Results - Earnings Call Transcript

Xencor (XNCR) delivered earnings and revenue surprises of 0.00% and -2.45%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Xencor (XNCR) Reports Q3 Loss, Misses Revenue Estimates

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the third quarter ended September 30, 2020 and provided a review of recent business and clinical highlights. "In 2020, we have reported advances for multiple programs in our clinical pipeline. Monjuvi® became the second drug with XmAb® Fc technology to receiv

Xencor Reports Third Quarter 2020 Financial Results

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that data from the ongoing Phase 1 dose-escalation study of vibecotamab (XmAb®14045), a CD123 x CD3 bispecific antibody, in patients with relapsed/refractory acute myeloid leukemia (AML) will be presented in an oral session at the 2020 American Society of Hematology (ASH) Annual M

Xencor to Present Data from Phase 1 Study of Vibecotamab in Acute Myeloid Leukemia at the 2020 ASH Annual Meeting

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will release third quarter 2020 financial results after the market closes on Thursday, November 5, 2020. Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update.

Xencor to Host Third Quarter 2020 Financial Results Webcast and Conference Call on November 5, 2020

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced four poster presentations at the 35th Annual Meeting of the Society for Immunotherapy of Cancer, being held virtually November 9-14, 2020. The presentations will include updated results from the ongoing Phase 1 dose-escalation and expansion study of XmAb®20717, a PD-1 x CTLA-4 bi

Xencor to Present Data from the Phase 1 Study of XmAb®20717 and Three Research Programs at the SITC Annual Meeting

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced initial data from its ongoing Phase 1 study of tidutamab (XmAb®18087), an SSTR2 x CD3 bispecific antibody, in patients with neuroendocrine tumors (NETs). The data were presented at the North American Neuroendocrine Tumor Society’s 2020 Multidisciplinary NET Medical Virtual Sympos

Xencor Presents Initial Data From the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc.

Xencor to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference

Xencor to Present Initial Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium

MONROVIA, Calif. & HOUSTON--(BUSINESS WIRE)--Xencor, Inc.

Xencor and MD Anderson Enter Strategic Collaboration to Advance Investigational XmAb® Drug Candidates

Dynavax Technologies

iShares Nasdaq Biotechnology ETF

ImmunoGen

Lexicon Pharmaceuticals

Viking Therapeutics

The second half of 2020 is well underway, and with markets recovering, one of the strongest industries leading the charge has been biotech.

News for Xencor Stock (XNCR)